Marlio Charles Mosseri Acquires 240,000 Shares of Nuvectis Pharma

Nuvectis Pharma, Inc. (NASDAQ:NVCT) has recently seen a significant acquisition by one of its major shareholders, Marlio Charles Mosseri. On February 7th, Mr. Mosseri purchased a total of 240,000 shares of the company's stock at an average price of $5.00 per share. This amounted to a total investment of $1,200,000. Following this purchase, his ownership stake in Nuvectis Pharma increased, resulting in a total of 2,884,121 shares directly owned, valued at approximately $14,420,605. This recent acquisition reflects a 9.08% increase in his position within the company. The details of this transaction were officially filed with the Securities and Exchange Commission (SEC) and can be accessed via their website.

Marlio Charles Mosseri's involvement with Nuvectis extends beyond this recent purchase, as he also acquired 17,000 shares back on December 13th for an average cost of $4.70 per share, totaling $79,900.

Nuvectis Pharma Stock Performance

As of midday trading on a Tuesday, shares of Nuvectis Pharma experienced a slight decline of 0.6%, dropping $0.04 to reach a price of $6.29. The trading volume was 54,546 shares, which is below the company's average volume of 119,724 shares. In terms of price movement, the stock has a 50-day simple moving average of $5.63 and has fluctuated between a low of $4.44 and a high of $12.10 over the past year. Nuvectis Pharma currently boasts a market cap of $121.52 million with a price-to-earnings ratio of -5.42, and its beta stands at 0.22, indicating lower volatility compared to the market.

Institutional Activity

There has been notable activity from institutional investors regarding Nuvectis Pharma stock. Several hedge funds have recently adjusted their holdings. For instance, Oppenheimer & Co. Inc. established a new position in Nuvectis Pharma during the last quarter, valued at approximately $135,000. Similarly, Nations Financial Group Inc. IA ADV increased its ownership by 35.0%, now holding 13,500 shares worth $73,000, after acquiring an additional 3,500 shares. Forbes J M & Co. LLP raised its stake by 21.9%, owning 59,000 shares valued at $319,000 following a purchase of 10,599 shares. Additionally, Baldwin Wealth Partners LLC MA lifted its position by 104.4%, now owning 355,961 shares valued at close to $1,926,000, and Geode Capital Management LLC boosted its holdings by 49.8% to own 79,716 shares worth approximately $501,000. These developments indicate strong institutional interest, with about 96.77% of the stock currently held by institutional investors.

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a biopharmaceutical company dedicated to developing precision medicines targeting significant unmet medical needs in oncology. The focal point of the company’s efforts is its lead product candidate, NXP800, a novel small molecule presently in Phase 1b clinical trials aimed at treating patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

Further Insights

Potential investors may consider examining various reports and analyses, including evaluations of other stocks that may serve as strong investment opportunities. Investigating factors such as historical performance, market trends, and analyst ratings can be beneficial in making informed decisions.

Nuvectis, Pharma, Insider